Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t able to pursue before the Gilead acquisition.

Pact is developing personalized autologous T cell therapies by identifying neoantigen-specific TCRs from patient blood and engineering their expression in fresh CD8 T cells (see “Pact Makes Case for Neoantigen-Specific TCRs”). ...